Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

Neurology

Volumn 60, Issue 10, 2003, Pages 1631-1637

  French, Jacqueline A ^a   Kugler, A R ^b   Robbins, J L ^a   Knapp, L E ^a   Garofalo, E A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ACCIDENT; ACCIDENTAL INJURY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; THOUGHT DISORDER; TREATMENT OUTCOME; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0038476172     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000068024.20285.65     Document Type: Article

References (31)

1. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-329.
2. Datta PK, Crawford PM. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 2000;9:51-57.
3. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-1174.
4. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs 1995;3:194-208.
5. 2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-5776.
6. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-236.
7. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-110.
8. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-1093.
9. 3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-196.
10. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 2002;51:31-71.
11. Taylor CP, Vartanian MG, Yuen PW, Bigge C, Suman-Chauhan N, Hill DR. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res 1993;14:11-15.
12. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001;132:1-4.
13. Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock. Epilepsia 1997;38(suppl 8):35-36.
14. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149-177.
15. Taylor CP, Vartanian MG, Profile of anticonvulsant activity of pregabalin in animal models. Epilepsia 1997;38(suppl 8):35.
16. Williamson J, Lothman CTE, Bertram E. Comparison of S-(+)-3 isobutyl GABA (pregabalin) and gabapentin against kindled hippocampal seizures. Epilepsia 1997;38(suppl 8):29.
17. Bockbrader HN, Hunt T, Strand J, Posvar E, Sedman A. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase 1 Studies. Neurology 2000;54(7, suppl 3):A421.
18. Bockbrader HN, Burger PJ, Corrigan BW, et al. Population pharmacokinetic (PK) analyses of pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia 2001;42(suppl 7):84.
19. Kugler AR, Robbins JL. Pregabalin exposure and pregabalin dose are equivalent predictors of seizure reduction. Neurology 2002;58(suppl 3):A295.
20. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-281.
21. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469-481.
22. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
23. Coding Symbols for a Thesaurus of Adverse Event Reaction Terms (COSTART), 4th ed. Department of Health and Human Services, US Food and Drug Administration, Rockville, MD, 1996.
24. Steel R, Torrie J. Principles and procedures of statistics. New York: McGraw-Hill, 1960:132-159.
25. Ruberg S. Contrasts for identifying the minimum effective dose. J Am Stat Assoc 1989;84:816-822.
26. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40:590-600.
27. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997;38(suppl 1):59-62.
28. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-222.
29. Arroyo S, Anhut H, Messmer S, Mathe H. Pregabalin double-blind add-on study in patients with partial seizures. Epilepsia 2001;42(suppl 7):83.
30. French JA, Malicsi MJR, Kugler AR, Knapp LE, Bockbrader HN, Garofalo EA. Pregabalin adjunctive therapy in patients with partial seizures. Epilepsia 1999;40(suppl 7):106.
31. Feng MR, Turluck D, Burleigh J, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001;26:123-128.